Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)

Nanjing Medical University

Status and phase: Not yet enrolling; Phase 2

Conditions: Colorectal Cancer (Diagnosis)

Treatments: Drug: Serplulimab; Drug: Bevacizumab; Drug: Chemotherapy (CAPOX or capecitabine); Radiation: Short-Course Radioterapy

Study type: Interventional

Funder types: Other

Identifiers

NCT07134101

2025-SR-610

Details and patient eligibility

About

The goal of this clinical trial is to learn if combining serplulimab (PD-1 inhibitor) with bevacizumab and short-course total neoadjuvant therapy (TNT) works to treat locally advanced mid-to-low rectal cancer in adults. It will also learn about the safety of this combination.

The main questions it aims to answer are:

Does adding bevacizumab to serplulimab and TNT increase the complete remission rate (cCR + pCR) compared with serplulimab and TNT alone? What medical problems do participants have when receiving these treatments?

Researchers will compare:

Experimental group: serplulimab + bevacizumab + chemotherapy + short-course radiotherapy Control group: serplulimab + chemotherapy + short-course radiotherapy

Participants will:

Receive either the experimental or control regimen for about 4-5 months before surgery or a watch-and-wait approach if complete response is achieved Undergo treatment in cycles that include chemotherapy, immunotherapy (and bevacizumab if in the experimental group), and short-course radiotherapy Visit the clinic regularly for check-ups, blood tests, imaging, endoscopy, and to monitor side effects Be followed for up to 5 years after treatment to assess cancer control, organ preservation, and survival outcomes

Enrollment: 138 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Participants must meet all of the following criteria to be eligible for the study:

1. Age: 18 to 75 years old.
2. Diagnosis: Pathologically confirmed rectal adenocarcinoma with proficient mismatch repair (pMMR) / microsatellite stable (MSS) status, based on biopsy of the primary tumor.
3. Disease Stage: Untreated, preoperative clinical stage cT2-T4 and/or N+, M0 (AJCC 8th edition), unsuitable for initial local excision to achieve radical cure.
4. Tumor Location: Tumor within 8 cm from the anal verge, or assessed by surgeons as not suitable for immediate sphincter-preserving surgery.
5. Organ Preservation Intent: Strong desire for sphincter preservation and willingness to accept close surveillance for at least 2 years after chemoradiotherapy.
6. Surgical Candidacy: Agrees to undergo radical surgery and judged by surgeon to have no contraindication to surgery.
7. Cancer History: No concurrent multiple primary malignancies.
8. Measurable Lesions: At least one measurable or evaluable lesion according to RECIST v1.1 criteria.
9. Life Expectancy: ≥ 3 months.
10. Performance Status: ECOG performance status score of 0-1.
11. Compliance: Good compliance and willingness to sign written informed consent.

Exclusion criteria

Participants will be excluded if any of the following conditions apply:

1. Molecular Subtype: Rectal cancer with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) status.

2. Autoimmune Disease: Active, known, or suspected autoimmune disease.

3. Immunodeficiency: Known history of primary immunodeficiency.

4. Transplant History: History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.

5. Pregnancy or Lactation: Pregnant or breastfeeding women.

6. Urgent Surgical Indications: Intestinal perforation, gastrointestinal bleeding, or other conditions requiring emergency surgery.

7. Uncontrolled Comorbidities, including but not limited to:

   HIV infection (HIV antibody positive) Active or poorly controlled severe infection Active hepatitis Severe or uncontrolled systemic diseases (e.g., severe psychiatric or neurological disorders, epilepsy, dementia, unstable or decompensated respiratory, cardiovascular, hepatic, or renal disease, uncontrolled hypertension ≥ CTCAE Grade 2 despite medication) Active bleeding or recent thrombotic disease requiring therapeutic anticoagulation, or bleeding tendency, or coagulation abnormalities (INR > 1.5 × ULN, APTT > 1.5 × ULN)

8. Laboratory Abnormalities at Baseline:

   Hemoglobin < 80 g/L Absolute neutrophil count (ANC) < 1.5 × 10⁹/L Platelets < 80 × 10⁹/L ALT or AST > 2.5 × ULN ALP > 2.5 × ULN Total bilirubin ≥ 1.5 × ULN Serum creatinine ≥ 1 × ULN

9. Allergy: Known hypersensitivity to any component of the investigational drugs.

10. Other Clinical Trial Participation: Currently enrolled in another interventional drug clinical trial.

11. Other Conditions: Any other condition judged by the investigator to make the patient unsuitable for the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

138 participants in 2 patient groups

Experimental Arm

Experimental group

Description:

Experimental Arm Induction Phase (2 cycles, every 3 weeks) Chemotherapy: CAPOX (capecitabine + oxaliplatin) or capecitabine monotherapy Capecitabine: 800 mg/m² orally, twice daily (BID), on Days 1-14 of each cycle Oxaliplatin: 130 mg/m² intravenous infusion, on Day 1 of each cycle (if CAPOX) Immunotherapy: Serplulimab 300 mg IV on Day 1 of each cycle Anti-angiogenic therapy: Bevacizumab 5 mg/kg IV on Day 1 of each cycle Radiotherapy: Short-course radiotherapy, 25 Gy in 5 fractions over 1 week Consolidation Phase 2 cycles of CAPOX or capecitabine + serplulimab + bevacizumab Followed by 2 cycles of CAPOX or capecitabine + serplulimab (no bevacizumab) Post-treatment After completion of neoadjuvant treatment, patients will undergo total mesorectal excision (TME) surgery or follow a Watch-and-Wait strategy if a clinical complete response (cCR) is achieved.

Treatment:

Radiation: Short-Course Radioterapy

Drug: Chemotherapy (CAPOX or capecitabine)

Drug: Bevacizumab

Drug: Serplulimab

Control Arm

Active Comparator group

Description:

Control Arm Induction Phase (2 cycles, every 3 weeks) Chemotherapy: CAPOX (capecitabine + oxaliplatin) or capecitabine monotherapy Capecitabine: 800 mg/m² orally, twice daily (BID), on Days 1-14 of each cycle Oxaliplatin: 130 mg/m² intravenous infusion, on Day 1 of each cycle (if CAPOX) Immunotherapy: Serplulimab 300 mg IV on Day 1 of each cycle Radiotherapy: Short-course radiotherapy, 25 Gy in 5 fractions over 1 week Consolidation Phase 4 cycles of CAPOX or capecitabine + serplulimab Post-treatment After completion of neoadjuvant treatment, patients will undergo total mesorectal excision (TME) surgery or follow a Watch-and-Wait strategy if a clinical complete response (cCR) is achieved.

Treatment:

Radiation: Short-Course Radioterapy

Drug: Chemotherapy (CAPOX or capecitabine)

Drug: Serplulimab